{"schema_version":"secwatch.filing_event.v1","accession":"0001722482-24-000142","form_type":"8-K","ticker":"AVTR","cik":"0001722482","company_name":"Avantor, Inc.","filed_at":"2024-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.271744+00:00","generated_at":"2026-05-31T15:58:47.225092+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Avantor reports Q2 net sales down 2.4% to $1.70B; GAAP EPS $0.14, adjusted $0.25","bullets":["Net sales $1.70B, down 2.4% YoY; organic decline 2.0% after FX impact.","Net income $93M vs ($7.3M) loss Q2 2023; GAAP diluted EPS $0.14, adjusted EPS $0.25.","Adjusted EBITDA $306M (17.9% margin); free cash flow $235M with >100% conversion.","Lab Solutions sales $1,155.7M (-3.2% reported), Bioscience Production $547.1M (-0.5%).","Fiscal 2024 guidance reaffirmed; adjusted net leverage 3.9x as of June 30."],"urls":{"canonical":"https://secwatch.observer/filing/0001722482-24-000142","json":"https://secwatch.observer/filing/0001722482-24-000142.json","markdown":"https://secwatch.observer/filing/0001722482-24-000142.md","text":"https://secwatch.observer/filing/0001722482-24-000142.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1722482/000172248224000142/0001722482-24-000142-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1722482/000172248224000142/avtr-20240726.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:58:47.225092+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}